Biocon · NSE: BIOCON · BSE: 532523
Q1 FY26 results · Apr–Jun 2025
Biocon reported revenue from operations of ₹3,941.90 crore (up 14.8% from Q1 FY25) and net profit of ₹89.20 crore (down 89.6% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,941.90 | 3,432.90 | +14.8% | 4,417.00 | −10.8% |
| Other income | 79.70 | 1,134.50 | −93.0% | 36.90 | +116.0% |
| Total income | 4,021.60 | 4,567.40 | −11.9% | 4,453.90 | −9.7% |
| Profit before tax | 96.90 | 1,145.50 | −91.5% | 486.80 | −80.1% |
| Net profit for the period | 89.20 | 861.80 | −89.6% | 459.40 | −80.6% |
| Attributable to shareholders of the company | 31.40 | 659.70 | −95.2% | 344.50 | −90.9% |
| EPS, basic (₹) | 0.26 | 5.51 | not comparable | 2.88 | not comparable |
| Net margin (%) | 2.3 | 25.1 | 10.4 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 537.10 | 510.60 | +5.2% | 643.80 | −16.6% |
| Other income | 61.30 | 41.90 | +46.3% | 62.70 | −2.2% |
| Total income | 598.40 | 552.50 | +8.3% | 706.50 | −15.3% |
| Profit before tax | (7.60) | 1.10 | Turned loss | 35.00 | Turned loss |
| Net profit for the period | (8.30) | 0.90 | Turned loss | 21.20 | Turned loss |
| EPS, basic (₹) | (0.07) | 0.01 | not comparable | 0.18 | not comparable |
| Net margin (%) | -1.5 | 0.2 | 3.3 |
Consolidated
- Filed with BSE
- 07 Aug 2025, 21:36 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Aug 2025, 21:36 IST
- Board meeting
- 07 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE